Protocol Ledger

NCT07047716 · Phase III · ACTIVE NOT RECRUITING

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

Interventional Phase III clinical trial protocol NCT07047716 sponsored by Gilead Sciences in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-22 Enrollment: 339 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07047716
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)339 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07047716
Protocol FieldVerified Registry Value
NCT IdentifierNCT07047716
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment339 participants (ACTUAL)
Registered Start Date2025-07-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI